The entire rate of grade 3 and grade 4 occasions at 60 times was 91.0 percent; 140 sufferers in the pasireotide group and 133 patients in the placebo group had a quality 3 or grade 4 adverse event. Nearly all these adverse events represented expected postoperative abnormalities in the total results of serum chemical analyses. Table 3Table 3Adverse Events Not Linked to Postoperative Pancreatic Fistula. Shows adverse events not linked to postoperative pancreatic fistula and adjudicated as possibly or probably related to pasireotide. Discussion This single-center, double-blind, placebo-controlled trial showed that treatment with pasireotide in the perioperative period significantly reduced the chance of clinically relevant postoperative pancreatic fistula, leak, or abscess., a late-stage biopharmaceutical business that develops, manufactures, and intends to advertise specialty plasma-structured biologics for the treatment and prevention of particular infectious diseases, announced its financial outcomes for the entire year ended December 31 today, 2013 and provided latest company developments along with anticipated milestones for 2014. ADMA Biologics achieved many significant milestones during 2013. We commenced and finished patient enrollment in our pivotal Phase III clinical research for RI-002 in patients who suffer from Primary Immune Deficiency Diseases .